WO2011030163A1 - Use of guaifenesin for inhibiting mucin secretion - Google Patents
Use of guaifenesin for inhibiting mucin secretion Download PDFInfo
- Publication number
- WO2011030163A1 WO2011030163A1 PCT/GB2010/051525 GB2010051525W WO2011030163A1 WO 2011030163 A1 WO2011030163 A1 WO 2011030163A1 GB 2010051525 W GB2010051525 W GB 2010051525W WO 2011030163 A1 WO2011030163 A1 WO 2011030163A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- guaifenesin
- administering
- effective amount
- approximately
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the use of a pharmaceutical compound for the inhibition of mucus secretion in an individual.- in particular, the present invention relates to the use of guaifenesin for the inhibition of mucus secretion.
- Guaifenesin whose chemical name is 3- 2-methoxypheno y)- 1 ⁇ -propanediol, ⁇ is an expectorant.
- An expectorant is a drug that helps bring up mucus and other material from the lungs, bronchi, and trachea.
- Guaifenesin is thought to act by thinning the mucus, loosening phlegm and bronchial secretions, and also by lubricating the irritated respiratory -tract By thinning , the mucus, guaifenesin reduces the viscosity of the- mucal.
- CGPP chronic obstructive pulmonary diseases
- inflammatory lung diseases asthma, cystic fibrosis and acute or chronic respiratory infectious diseases using compounds of a defined formula having at least two aromatic rings.
- the applicant has developed a method of inhibiting the secretion of mucus in an. individual which comprises administering an effect ve amount of a composition- -which comprises guaifenesin..
- a method of inhibiting rmicus secretion in an individual which comprises administering an effective amount. •of a composition which comprises guaifenesin.
- the composition can contain from approximately 600mg- 1200mg o f guai fenesin.
- the guaifenesin can be administered in many suitable forms such as a tablet, powder, capsule, liquid or liquigel.
- the guaifenesin can be administered orally.
- the mucin can be produced in the upper respiratory tract of an individual.
- Tire composition can contain one or more additional active agents selected from the group including, but. not limited to, an antitussive such as dextromethorphan hydrobromide, a decongestant such as phenylephrine hydrochloride, pseudoephedrine hydrochloride or ⁇ ephedrine, • an antihistamine such as chlorpheniramine maieate, brompheniramine maieate, phenindamine tartrate, pyrilamine maieate, doxylamine succinate, phenyitoloxamine citrate, diphenhydramine hydrochloride, promethazine, and clemastine fumerate. fexofenadine or a combination thereo
- an antitussive such as dextromethorphan hydrobromide
- a decongestant such as phenylephrine hydrochloride, pseudoephedrine hydrochloride or ⁇ ephedrine
- an antihistamine such as chlorpheniramine
- the composition can have an immediate release portion and a sustained release poition, such that the inhibition of mucus secretion, is therapeutically achieved for a period of approximately ⁇ 2 hours.
- the daily dose of guaifenesin can be 24O0mg.
- a method of treating an individual having a disease or condition characterized by increased mucin secretion with an effective amount of a composition which comprises guaifenesin as described in the first aspect of the present invention is provided.
- the disease of condition characterized by -increased mucin secretion infectious can be selected from inflammatory conditions of the airways.
- Fig, 1 illustrates the treatment protocol.
- Fig. 2 is a graph showing the effect of guaifenesin on MUC5 AC mucin secretion: 30 mm
- Figs. 3a and 3b are graphs showing the effect of guaifenesin on MUC5AG mucin secretion: 6 hours
- Figs. 4a and 4b are graphs showing the effect of guaifenesin on MUC5AC mucin secretion: 24 hours
- Figs. Sa and 5b are graphs showing the effect of guaifenesin on MUC5AC mucin secretion: 48 hours
- Fig, 6 is a graph showing the effect of guaifenesin on mucociliary clearance.
- Figs. 7a and 7b are graphs showing metabolic activity.
- Figs. 8a, 8 b and 8c are graphs showing mucus theology.
- Figs. 9a and 9b are graphs sho wing the vector sum of viscosity and elasticity against time and dose
- EpiAirway cultures normal human bronchial epithelial cells grown on Millipore Transwells, 1 or 4.2 cm 2 surface area. The cells were purchased from MatTek, and were cultured, at air-liquid interface for two (mucus synthesis and secretion) or three (mucociliary transport and mucus rheoiogy) weeks prior to use.
- a stock guaifenesin solution of 2 mg/mL in culture medium was prepared in the morning of each experiment, and kept cold until dilution into warmed medium to the target concentrations of 0,2, 2, 20 or 200 ⁇ g/mL.
- the medium in the basolateral compartment of each culture was replaced with the GGE-contammg medium, and the cultureswere returned to the 37°C, 5% CO 2 incubator for as the times indicated.
- the experiments were repeated three times on independent cultures.
- concentrations used in the in vitro experiments range from 0.2 ⁇ g/mL to 20 mg/mL and thus bracket the clinical doses used in humans.
- GUAIFENESIN solutions were prepared by dissolving in PBS .(phosphate buffered saline) immediately before treatment of the cells.
- MUC5AC mucins were quantified by BLISA using 45MI antibody (Lab vis ion, Fremont, CA).
- Confluent 1 cm * NHBE cells grown on an air/liquid interface were washed from the apical surface with 200 p.L PBS and incubated with fresh, complete growth medium added to the basal chamber. Cultures were incubated 24 hours to collect the apical fluid (pretreatment sample or PT) by adding 100 PBS to the apical, surface of the cultures.
- PBS was added to dilute the highly viscous, thin mucus layer on the surface. Because of the .small size of the insert, it was not feasible to collect a sufficient amount of mucus for both pharmacology and rheology without the addition of PBS.
- PT mucus samples
- cultures were divided into three groups (6 hr, 24 hr and 48 hr), 16 inserts per group, and treated with varying concentrations of guaifenesin (0, 0,2, 2, 20 ⁇ g/mL) for each time group, 4 inserts per each dose. Thus, a total of 48 inserts were used for this study ⁇ 4 inserts/dose x 4 doses/time point x 3 time points).
- the apical fluid was ' collected at 30 minutes following drug treatment front all the cultures to see whether guaifenesin affects the "secretion" of mucins.
- the apical, mucus sample was collected in two steps ⁇ first by adding 100 ⁇ . ⁇ PBS to the apical surface ( 1 st wash) and then by adding 100 ⁇ L ⁇ PBS containing 5 mM dilhiothreitol (DTT) (2" a wash). Samples from each wash were assayed for MUC5AC content and the sum of the two values (the 1 st and 2TM wash.) was expressed. -as the '"released MUC5AC" of the culture.
- Cultures (4.2 cm.') were exposed to basolaieral guaifenesin for 1 or 6 hr. The cultures were removed from the incubator and placed on. the stage of digital imaging microscopy system . Video data were collected for 10 seconds using a. 25x objective. The rate of movement of endogenous cell, debris -was analyzed on the video images using a transparent template overlay on the video images and a stopwatch to measure at least 5 particles on each culture, for a total of between 30 and 45 .measurements per condition.
- mucus was harvested from the apical surface of the cultures, without dilution.
- the rheologieal properties of apical mucus secretions (20 p.L) were measured using art ARI000 controlled stress rheometer (TA Instruments:, New Castle, DE) using a parallel plate ⁇ geometry.
- Rheologie data can also be presented using vectorial notation .as tangent ⁇ which is the ratio of viscosity to elasticity and G*, the vector sum of viscosity and elasticity (mechanical impedance).
- Fig. 3a the white boxes represent the amount of mucin associated with, the cell, whereas the black boxes represent the amount of mucin released during the given period of treatment. Therefore, the addition of the white box. and the black box represents the total amount of mucin produced during the given period.
- the total amounts ofMUC5 AC- were compared for statistical differences between control (no guaifenesin) and guaifenesin groups.
- guaifenesin appeared to increase the mobility of the cellular debris on the surface of cultures treated for 1 hr, but there was little evidence of a dose-response and in fact, only the effect of 2 ⁇ g/ l was statistically significant. However, at the 6 hr time point, there was a strong trend to a dose response and movement of the -surface material for all three concentrations tested was significantly faster than the control as illustrated -in.
- EpiAirway cultures were treated with the indicated concentrations of guaifenesin ⁇ b.r 1 or 6 his. Mucociliary clearance was assessed, by the rate of mo vement of endogenous debris on. the surfaces. *** indicates significantly different from- the control cultures- at the same time, p ⁇ 0.00.5.
- G* vector sum of viscosity and elasticity, at 1 rad-'s (Fig. 9a) arid 100 rad/sec (Fig. 9b), segregated by time as well as dose.
- Viscosity is the loss of energy from a rheoSogie probe or applied, stress and thus the resistance to flow.
- Elasticity storage modulus.
- the complex modulus, G* is also known as the mechanical impedance..
- G* measurement indicates -resistance lo deformation.
- Viscoelasiieity is a property of non-Newtonian fluids (gels). Dynaraie viseoelasticity measures •the strain response of mucus to an applied stress. Because mucus is subjected- to both low -stress (ciliary beat) and high stress (cough) conditions, we measure the strain developed in response to a dynamic stress.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10757117A EP2475360A1 (en) | 2009-09-12 | 2010-09-13 | Use of guaifenesin for inhibiting mucin secretion |
RU2012114323/15A RU2012114323A (en) | 2009-09-12 | 2010-09-13 | APPLICATION OF GUYPHENESIN TO INHIBIT MUCIN SECRETION |
CN2010800492171A CN102596189A (en) | 2009-09-12 | 2010-09-13 | Use of guaifenesin for inhibiting mucin secretion |
BR112012005517A BR112012005517A2 (en) | 2009-09-12 | 2010-09-13 | use of guaifenesin to inhibit mucin secretion |
MX2012003042A MX2012003042A (en) | 2009-09-12 | 2010-09-13 | Use of guaifenesin for inhibiting mucin secretion. |
JP2012528455A JP2013504554A (en) | 2009-09-12 | 2010-09-13 | Use of guaifenesin to suppress mucin secretion |
CA2773611A CA2773611A1 (en) | 2009-09-12 | 2010-09-13 | Use of guaifenesin for inhibiting mucin secretion |
AU2010294008A AU2010294008B2 (en) | 2009-09-12 | 2010-09-13 | Use of guaifenesin for inhibiting mucin secretion |
ZA2012/01822A ZA201201822B (en) | 2009-09-12 | 2012-03-13 | Use of guaifenesin for inhibiting mucin secretion |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/558,517 | 2009-09-12 | ||
US12/558,517 US20110065744A1 (en) | 2009-09-12 | 2009-09-12 | Method Of Inhibiting Mucin Secretion |
GB1002039.4 | 2010-02-09 | ||
GBGB1002039.4A GB201002039D0 (en) | 2010-02-09 | 2010-02-09 | Method of inhibiting mucin secretion |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011030163A1 true WO2011030163A1 (en) | 2011-03-17 |
Family
ID=42941393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2010/051525 WO2011030163A1 (en) | 2009-09-12 | 2010-09-13 | Use of guaifenesin for inhibiting mucin secretion |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2475360A1 (en) |
JP (1) | JP2013504554A (en) |
KR (1) | KR20120068889A (en) |
CN (1) | CN102596189A (en) |
AU (1) | AU2010294008B2 (en) |
BR (1) | BR112012005517A2 (en) |
CA (1) | CA2773611A1 (en) |
MX (1) | MX2012003042A (en) |
MY (1) | MY161187A (en) |
RU (1) | RU2012114323A (en) |
WO (1) | WO2011030163A1 (en) |
ZA (1) | ZA201201822B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104619321A (en) * | 2012-04-06 | 2015-05-13 | Uab研究基金会 | Methods for increasing cftr activity |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102211605B1 (en) * | 2018-02-26 | 2021-02-04 | 대한민국 | Methods for Screening Therapeutic Agents for Airway Conduct MucinSecretion Inhibitor Using the Frog Embryo |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996035452A1 (en) * | 1995-05-10 | 1996-11-14 | Adcock Ingram Limited | Pharmaceutical composition containing acetylcysteine, carbocysteine or erdosteine in combination with a beta 2 agonist and an expectorant for the treatment of respiratory tract disorders |
WO2004113286A2 (en) * | 2003-06-19 | 2004-12-29 | Genaera Corporation | Mucin synthesis inhibitors |
US20050095288A1 (en) * | 2003-11-03 | 2005-05-05 | Andrx Labs, Llc | Decongestant and expectorant tablets |
US20050266032A1 (en) * | 2003-12-17 | 2005-12-01 | Sovereign Pharmaceuticals, Ltd. | Dosage form containing multiple drugs |
US20080014261A1 (en) * | 2006-07-12 | 2008-01-17 | Giordano John A | Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction |
US20090202633A1 (en) * | 2008-01-03 | 2009-08-13 | Siva Ramakrishna Velaga | Extended release formulations of guaifenesin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6846799B1 (en) * | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
US7985420B2 (en) * | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
CA2474016A1 (en) * | 2002-02-04 | 2003-08-14 | Pharmacia Corporation | A combination for treating cold and cough |
-
2010
- 2010-09-13 MX MX2012003042A patent/MX2012003042A/en unknown
- 2010-09-13 WO PCT/GB2010/051525 patent/WO2011030163A1/en active Application Filing
- 2010-09-13 AU AU2010294008A patent/AU2010294008B2/en active Active
- 2010-09-13 RU RU2012114323/15A patent/RU2012114323A/en unknown
- 2010-09-13 KR KR1020127007996A patent/KR20120068889A/en not_active Application Discontinuation
- 2010-09-13 CN CN2010800492171A patent/CN102596189A/en active Pending
- 2010-09-13 CA CA2773611A patent/CA2773611A1/en not_active Abandoned
- 2010-09-13 MY MYPI2012001112A patent/MY161187A/en unknown
- 2010-09-13 JP JP2012528455A patent/JP2013504554A/en active Pending
- 2010-09-13 BR BR112012005517A patent/BR112012005517A2/en not_active Application Discontinuation
- 2010-09-13 EP EP10757117A patent/EP2475360A1/en not_active Ceased
-
2012
- 2012-03-13 ZA ZA2012/01822A patent/ZA201201822B/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996035452A1 (en) * | 1995-05-10 | 1996-11-14 | Adcock Ingram Limited | Pharmaceutical composition containing acetylcysteine, carbocysteine or erdosteine in combination with a beta 2 agonist and an expectorant for the treatment of respiratory tract disorders |
WO2004113286A2 (en) * | 2003-06-19 | 2004-12-29 | Genaera Corporation | Mucin synthesis inhibitors |
US20050095288A1 (en) * | 2003-11-03 | 2005-05-05 | Andrx Labs, Llc | Decongestant and expectorant tablets |
US20050266032A1 (en) * | 2003-12-17 | 2005-12-01 | Sovereign Pharmaceuticals, Ltd. | Dosage form containing multiple drugs |
US20080014261A1 (en) * | 2006-07-12 | 2008-01-17 | Giordano John A | Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction |
US20090202633A1 (en) * | 2008-01-03 | 2009-08-13 | Siva Ramakrishna Velaga | Extended release formulations of guaifenesin |
Non-Patent Citations (2)
Title |
---|
REICHARD W: "Myocaine E in the treatment of bronchial asthma", WIENER MEDIZINISCHE WOCHENSCHRIFT 1951, vol. 101, no. 13, 1951, pages 244 - 245, XP009140375, ISSN: 0043-5341 * |
SCHAFFER K: "[Treatment of chronic bronchitis and bronchial asthma with aerosols of myocain E.]", WIENER MEDIZINISCHE WOCHENSCHRIFT (1946) 17 NOV 1951 LNKD- PUBMED:14922837, vol. 101, no. 46, 17 November 1951 (1951-11-17), pages 886, XP009140377, ISSN: 0043-5341 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104619321A (en) * | 2012-04-06 | 2015-05-13 | Uab研究基金会 | Methods for increasing cftr activity |
EP2833885A4 (en) * | 2012-04-06 | 2015-12-16 | Uab Research Foundation | Methods for increasing cftr activity |
Also Published As
Publication number | Publication date |
---|---|
AU2010294008A1 (en) | 2012-04-05 |
JP2013504554A (en) | 2013-02-07 |
MY161187A (en) | 2017-04-14 |
KR20120068889A (en) | 2012-06-27 |
ZA201201822B (en) | 2013-05-29 |
CA2773611A1 (en) | 2011-03-17 |
BR112012005517A2 (en) | 2016-04-19 |
AU2010294008B2 (en) | 2014-08-14 |
EP2475360A1 (en) | 2012-07-18 |
MX2012003042A (en) | 2012-05-29 |
CN102596189A (en) | 2012-07-18 |
RU2012114323A (en) | 2013-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sommerhoff et al. | Mast cell chymase. A potent secretagogue for airway gland serous cells. | |
CN102612564B (en) | New anti-ageing reagent and discrimination method thereof | |
Wang et al. | Cigarette smoke inhibits human bronchial epithelial cell repair processes | |
Corcelle et al. | Disruption of autophagy at the maturation step by the carcinogen Lindane is associated with the sustained mitogen-activated protein kinase/extracellular signal–regulated kinase activity | |
Seagrave et al. | Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells | |
Rogers | Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options | |
Mishra et al. | Purinergic P2X7 receptor regulates lung surfactant secretion in a paracrine manner | |
Profita et al. | Smoke, choline acetyltransferase, muscarinic receptors, and fibroblast proliferation in chronic obstructive pulmonary disease | |
Giuliani et al. | Ethanol and acetaldehyde inhibit the formation of early osteoblast progenitors in murine and human bone marrow cultures | |
Kumar et al. | Whole urinary proteins coat calcium oxalate monohydrate crystals to greatly decrease their adhesion to renal cells | |
Li et al. | Low-dose cadmium exposure induces peribronchiolar fibrosis through site-specific phosphorylation of vimentin | |
Wang et al. | Two major inositol transporters and their role in cryptococcal virulence | |
Wen et al. | Denatonium inhibits growth and induces apoptosis of airway epithelial cells through mitochondrial signaling pathways | |
Ajonuma et al. | Characterization of epithelial cell culture from human hydrosalpinges and effects of its conditioned medium on embryo development and sperm motility | |
Fornai et al. | Fine ultrastructure and biochemistry of PC12 cells: a comparative approach to understand neurotoxicity | |
Sadvakassova et al. | Active hematopoiesis triggers exosomal release of PRDX2 that promotes osteoclast formation | |
EP2475360A1 (en) | Use of guaifenesin for inhibiting mucin secretion | |
Del Carmen Velazquez Pereda et al. | Expression of differential genes involved in the maintenance of water balance in human skin by Piptadenia colubrina extract | |
Pietras et al. | Estrogen-induced membrane alterations and growth associated with proteinase activity in endometrial cells. | |
Wang et al. | Lung specific homing of diphenyleneiodonium chloride improves pulmonary fibrosis by inhibiting macrophage M2 metabolic program | |
Sahara et al. | Specific biological functions of vacuolar‐type H+‐ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts | |
Namba et al. | Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes | |
US20170196821A1 (en) | Method of Inhibiting Mucin Secretion | |
Keating et al. | The effect of a series of organic cations upon the plasmalemmal serotonin transporter, SERT | |
Kuroda et al. | Perturbation of lamellar granule secretion by sodium caprate implicates epidermal tight junctions in lamellar granule function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080049217.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10757117 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2773611 Country of ref document: CA Ref document number: 2012528455 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010294008 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/003042 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010757117 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20127007996 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2010294008 Country of ref document: AU Date of ref document: 20100913 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3175/CHENP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012114323 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012005517 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012005517 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120312 |